1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
- 2017
- Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets
- Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
- Genomic Amplifications and Distal 6q Loss are Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
- 2016
- Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients
- Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
- Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
- 2015
- Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
- Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers
- 2014
- Genome-wide methylation analysis unravels differential DNA methylation patterns between (prognostic) neuroblastoma patient subgroups